Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)

Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

(2012) N. Gokbuget et al.   BLOOD

Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia

(2012) Wendy Stock et al.   CANCER

Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults

(2011) Eric S. Schafer et al.   Nature Reviews Clinical Oncology

Adult acute lymphoblastic leukemia

(2010) Stefan Faderl et al.   CANCER

Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia

(2010) Misato Kikuchi et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: A report from the Japanese Childhood Cancer and Leukemia Study Group

(2010) Kazutaka Yamaji et al.   PEDIATRIC BLOOD & CANCER

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

(2009) R. Bassan et al.   BLOOD

Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study

(2009) Françoise Huguet et al.   JOURNAL OF CLINICAL ONCOLOGY

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies

(2008) W. Stock et al.   BLOOD

Comparison of the Results of the Treatment of Adolescents and Young Adults With Standard-Risk Acute Lymphoblastic Leukemia With the Programa Español de Tratamiento en Hematología Pediatric-Based Protocol ALL-96

(2008) Josep-María Ribera et al.   JOURNAL OF CLINICAL ONCOLOGY